Drugs / ZYG24002
last change Apr 2026 re-read 3 minutes ago

ZYG24002

Developed for
seborrheic dermatitis
Investigated by
Sinomune Pharmaceutical Co., Ltd

Trials 1

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07404033 Apr → Dec 2026 expected seborrheic dermatitis Sinomune Pharmaceutical Co., Ltd Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ZYG24002 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07404033 ↗
Route Topical “continuous topical application” NCT07404033 ↗